Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4659 Current role of systemic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) sporadic and hereditary

Introduction: Retrospective, performed in prospective manner single-arm, open-label, case series study to assess the efficacy of lanreotide in patients with unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations.

Conference:

Presenting Author:

Authors: Kolasińska-Ćwikla A, Pęczkowska M, Michałowska I, Pałucki J, Roszkowska-Purska K,

Keywords: Paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations, Lanreotide therapy, fractionated metoxycatecholamines,

#4589 Clinical efficacy of RLT to assess OS and PFS using 177Lu DOTATATE, 90Y DOTATATE, and a mixture of both in patients with advanced, unresectable, progressive rectal NET – A retrospective analysis

Introduction: Retrospective, single-arm, open-label, case series study evaluating the efficacy of different types of radioligand therapy (RLT): 177Lu, 90Y DOTATATE, or mix of both used in advanced, unresectable progressive rectal NETG1/G2.

Conference:

Presenting Author: Ćwikła J

Authors: Kolasińska-Ćwikla A, Sankowski A, Pałucki J, Sekelcka N, Ćwikła J,

Keywords: Rectal Neuroendocrine Tumour, SST Receptor, Radioligand Therapy (RLT),

#3826 Prognostic value of the neutrophil/lymphocyte ratio (NLR) in advanced, non resectable, progressive pancreatic and midgut NET after combine therapy using Lu-177 DOTATOC and CAPTEM

Introduction: Previous data suggest neutrophil/lymphocyte ratios (NLRs) could be used as prognostic factor in various solid tumors.

Conference:

Presenting Author: Kolasińska-Ćwikła A

Authors: Ćwikła J, Kolasińska-Ćwikła A, Zrajkowska A, Pałucki J, Seklecka N,

Keywords: Neuroendocrine Tumor, Receptor, Somatostatin, CAPTEM radioligand therapy (RLT), Progression-Free Survival, Neutrophil lymphocyte ratio,

#3495 PFS evaluation in patients with advanced, non-resectable, progressive GEP-NET treated using combine radioligand/PRRT and CAPTEM therapy

Introduction: Prospective, single-arm, open-label, case series study with assessment the efficacy and safety of combined radioligand therapy (RLT/PRRT) and CAPTEM in advanced, non-resectable progressive GEP-NET (NCT04194125).

Conference:

Presenting Author: Ćwikła J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Zrajkowska A, Nowicka G, Pałucki J,

Keywords: neuroendocrine tumor, combine therapy PRRT and CAPTEM, PFS,

#3267 High efficacy of combined PRRT and CAPTEM therapy based on objective response rate (RECIST) in patients with pancreatic and midgut neuroendocrine tumors (NET)

Introduction: PRRT and chemotherapy might be an option.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Kolasińska-Ćwikła A

Authors: Kolasińska-Ćwikła A, Nowicki , Zrajkowska A, Pałucki , Nowicka G,

Keywords: neuroendocrine tumor, pancreatic, midgut, DCR, ORR,